Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 07/30/24
Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumorGlobeNewsWire • 07/25/24
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric CancersGlobeNewsWire • 06/18/24
Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain TumorGlobeNewsWire • 04/23/24
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate ProgressGlobeNewsWire • 02/26/24
Navigating Day One Biopharmaceuticals' Financial Health And Clinical ProspectsSeeking Alpha • 02/01/24
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)GlobeNewsWire • 10/30/23
Day One Biopharmaceuticals: NDA Filing Decision Is An Inflection Point To WatchSeeking Alpha • 09/15/23
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)GlobeNewsWire • 09/12/23
Day One Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 06/12/23